Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1

Interventions

pembrolizumab 245Nivolumab 141Cisplatin 137Cyclophosphamide 134Paclitaxel 115Carboplatin 108Gemcitabine 98Radiotherapy 84Dexamethasone 83Docetaxel 77atezolizumab 69Ipilimumab 67Fluorouracil 61Doxorubicin 61Blood Specimen Collection 59Bevacizumab 59Rituximab 55fludarabine 54Etoposide 53Oxaliplatin 52Lenalidomide 50Surveys and Questionnaires 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Radiosurgery 44Cetuximab 44lenvatinib 43Capecitabine 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × vinflunine × 1 year × Clear all
NCT04527991 2026-06-02

TROPiCS-04

Gilead Sciences

Phase 3 Completed
711 enrolled 25 charts
Genitourinary

Locally Advanced or Metastatic Unresectable Urothelial Cancer

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Astellas Pharma Inc

Phase 3 Completed
608 enrolled 22 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡